Zoetis Inc (ZTS)
169.56
+0.12
(+0.07%)
USD |
NYSE |
May 31, 16:00
169.61
+0.05
(+0.03%)
After-Hours: 20:00
Zoetis Enterprise Value: 81.98B for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 81.98B |
| May 30, 2024 | 81.92B |
| May 29, 2024 | 82.54B |
| May 28, 2024 | 82.77B |
| May 24, 2024 | 82.21B |
| May 23, 2024 | 82.59B |
| May 22, 2024 | 83.11B |
| May 21, 2024 | 83.45B |
| May 20, 2024 | 84.18B |
| May 17, 2024 | 84.03B |
| May 16, 2024 | 83.87B |
| May 15, 2024 | 83.67B |
| May 14, 2024 | 81.66B |
| May 13, 2024 | 81.22B |
| May 10, 2024 | 81.74B |
| May 09, 2024 | 81.32B |
| May 08, 2024 | 79.86B |
| May 07, 2024 | 81.47B |
| May 06, 2024 | 80.33B |
| May 03, 2024 | 80.84B |
| May 02, 2024 | 80.91B |
| May 01, 2024 | 76.93B |
| April 30, 2024 | 77.27B |
| April 29, 2024 | 77.48B |
| April 26, 2024 | 76.89B |
| Date | Value |
|---|---|
| April 25, 2024 | 74.68B |
| April 24, 2024 | 73.55B |
| April 23, 2024 | 72.95B |
| April 22, 2024 | 71.11B |
| April 19, 2024 | 71.55B |
| April 18, 2024 | 74.57B |
| April 17, 2024 | 74.04B |
| April 16, 2024 | 74.53B |
| April 15, 2024 | 73.04B |
| April 12, 2024 | 73.14B |
| April 11, 2024 | 78.97B |
| April 10, 2024 | 79.18B |
| April 09, 2024 | 80.98B |
| April 08, 2024 | 80.32B |
| April 05, 2024 | 80.40B |
| April 04, 2024 | 80.24B |
| April 03, 2024 | 79.08B |
| April 02, 2024 | 80.01B |
| April 01, 2024 | 80.93B |
| March 31, 2024 | 81.93B |
| March 28, 2024 | 81.84B |
| March 27, 2024 | 81.59B |
| March 26, 2024 | 80.29B |
| March 25, 2024 | 81.27B |
| March 22, 2024 | 81.77B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
48.55B
Minimum
Mar 23 2020
120.20B
Maximum
Dec 29 2021
81.38B
Average
81.44B
Median
Enterprise Value Benchmarks
| IDEXX Laboratories Inc | 41.59B |
| Eli Lilly and Co | 803.37B |
| Pfizer Inc | 219.46B |
| ResMed Inc | 31.08B |
| Amgen Inc | 218.38B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 599.00M |
| Revenue (Quarterly) | 2.19B |
| Total Expenses (Quarterly) | 1.389B |
| EPS Diluted (Quarterly) | 1.31 |
| Gross Profit Margin (Quarterly) | 70.64% |
| Profit Margin (Quarterly) | 27.35% |
| Earnings Yield | 3.06% |
| Operating Earnings Yield | 4.02% |
| Normalized Earnings Yield | 3.094 |